Cytarabine: Therapeutic Trials and Editorial Standards
Authors: PETER H. WIERNIK
Journal: Annals of Internal Medicine (1975)

Comments and Correction1 October 1975Cytarabine: Therapeutic Trials and Editorial StandardsPETER H. WIERNIK, M.D.PETER H. WIERNIK, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-83-4-578 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Dr. Kremer states in his review of the usefulness of cytarabine (Ann Intern Med82:684-688, 1975) that "three different regimens involving combinations of cytarabine with other active agents have consistently produced a complete remission rate greater than 50% in adults" (with acute myeloblastic leukemia), and he cites the work of Clarkson (1), Crowther and associates (2), and Whitecar and colleagues (3). Actually, the complete remission rates in the studies cited are somewhat lower than Dr. Kremer indicates. The latest evaluation of the Clarkson study shows a complete remission rate of 56% in 88 previously untreated patients with...References1. CLARKSON B: Acute myelocytic leukemia in adults. Cancer 30:1572-1582, 1972 CrossrefMedlineGoogle Scholar2. CROWTHERPOWLERBATEMAN DRC: Management of adult acute myelogenous leukemia. Br Med J 1:131-137, 1973 CrossrefMedlineGoogle Scholar3. WHITECARBODEYFREIREICH JGE: Cyclophosphamide (NSC 26271), vincristine (NSC 6754), cytosine arabinoside (NSC 63878), and prednisone (NSC 10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep 56:543-550, 1972 MedlineGoogle Scholar4. CLARKSON B: Personal communication. April, 1975 Google Scholar5. WIERNIKGLIDEWELLHOLLAND POJ: Comparison of daunorubicin with cytosine arabinoside and thioguanine, and with a combination of all 3 drugs for induction therapy of previously untreated AML. Proc Am Assoc Cancer Res 16:82, 1975 Google Scholar6. POWLESCROWTHERBATEMAN RDC: Immunotherapy for acute myelogenous leukemia. Br J Cancer 28:365-376, 1973 CrossrefMedlineGoogle Scholar7. : A cooperative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicin) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukemia. Biomedicine 18:192-198, 1973 MedlineGoogle Scholar8. : A second cooperative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicin) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukemia. Eur J Cancer 10:413-418, 1974 CrossrefMedlineGoogle Scholar9. BODEYCOLTMAN GC: Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide. Arch Intern Med 133:260-266, 1974 CrossrefMedlineGoogle Scholar10. MCCREDIEBODEYBURGESS KGM: The management of acute leukemia in adults. Proceedings of the 14th Annual Clinical Conference, M.D. Anderson Hospital. In press, 1975 Google Scholar11. RAIHOLLANDGLIDEWELL KJO: Improvement in remission induction therapy of acute myelocytic leukemia. Proc Am Soc Clin Oncol 16:265, 1975 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PETER H. WIERNIK, M.D.Affiliations: Section of Medical Oncology National Cancer Institute Baltimore Cancer Research Center 22 South Greene Street Baltimore, Maryland 21201 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1975Volume 83, Issue 4Page: 578-578KeywordsAcute myeloid leukemia ePublished: 1 December 2008 Issue Published: 1 October 1975 PDF downloadLoading ...